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ABSTRACT 
 
 
Background:  Over 240 million people worldwide are affected by type II 
diabetes, and this number is expected to rise to over 380 million by the year 
2025. As type II diabetes becomes exponentially more prevalent in our society, 
novel treatment options should be explored. Currently, the management of type II 
diabetes focuses on the prevention of disease progression through lifestyle 
modifications and medical therapy. Although there have been advances in the 
pharmacological treatment of type II diabetes, it still remains a poorly controlled 
disease. Emerging data suggest that bariatric surgery may provide a more 
sustained and effective treatment for type II diabetes.  
 
Method:  An extensive search of the literature using MEDLINE, PUBMED, 
UPTODATE and CINAHL were performed to identify the effects of gastric bypass 
surgery on type II diabetes for the purpose of performing a systematic review and 
assessing the outcomes using the GRADE system. Two randomized control 
trials, and one cohort study were identified. 
 
Results:  Based on the two randomized control trials and one cohort study, 
showed that the efficacy of gastric bypass surgery was significantly greater than 
diet and medication without surgery, in the treatment of type II diabetes in terms 
of reducing HbA1C and fasting plasma glucose.   
 
Conclusion: Overall, the use of gastric bypass surgery in the treatment of type II 
diabetes significantly reduces HbA1c, fasting plasma glucose and the use of 
pharmacotherapy. This review of the outcomes using the GRADE system 
confirms the effectiveness of bariatric surgery as a therapy for type II diabetes.  
 
Keywords:  type 2 diabetes, gastric bypass 
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Background 
Type II diabetes mellitus is a major endocrine disorder that is 
characterized by the development of insulin resistance and a progressive 
reduction in insulin secretion by the pancreas. The development of type II 
diabetes is strongly associated with obesity and the accumulation of abdominal 
and ectopic fat. These fat deposits have been linked to peripheral and hepatic 
insulin resistance, inflammation and subsequent toxicity of β-cells. Approximately 
240 million people are currently afflicted with type II diabetes, and the number is 
expected to exceed 380 million by the year 2025 (Rubino, Kaplan, Schauer, 
Cummings, 2010). As type II diabetes becomes exponentially more prevalent in 
our society, novel treatment options should be explored.  
Currently, the management of type II diabetes focuses on the prevention 
of disease progression through lifestyle modifications and medical therapy. 
Although there have been tremendous advances in the pharmacological 
treatment of type II diabetes, it still remains a poorly controlled disease. 
Emerging data suggest that bariatric surgery may provide a more sustained and 
effective treatment for obesity and related morbidities such as hyperglycemia and 
type II diabetes. Initial reports indicate that improved control of type II diabetes 
could be seen a few weeks to months after surgery. Recently it has been seen 
that these improvements may take place much soon after surgery and before 
weight loss has even taken place (Wickremesekera, Miller, Naotunne, Knowles & 
Stubbs, 2005). Several hypotheses for this have been proposed but regardless of 
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the mechanism, endeavors to find more effective therapies for type II diabetes 
should be explored. 
Bariatric surgery procedures are divided into three categories: 
malabsorptive, restrictive and combined malabsorptive and restrictive. 
Malabsorptive procedures develop weight loss by decreasing nutrient absorption 
due to small intestine shortening (Spanakis & Gragnoli, 2009). These procedures 
have been limited due to increased mortality and complications. Gastric 
restrictive surgeries including the laparoscopic adjustable gastric band (LAGB) 
and laparoscopic sleeve gastrectomy (LSG) restrict stomach capacity to limit the 
intake of solid food and calories. The most common type of bariatric surgery 
done today is the roux-en-y bypass (RYGB), which is both malabsorptive and 
restrictive. In a RYGB, the stomach is made smaller by creating a small pouch at 
the top of the stomach using surgical staples or a plastic band. The smaller 
stomach is then connected directly to the middle portion of the small intestine 
(jejunum), bypassing the rest of the stomach and the upper portion of the small 
intestine (duodenum).  
There is now considerable evidence that operations previously performed 
as weight loss procedures, are able to induce long-term diabetes remission in 
most cases. The Roux en y gastric bypass (RYGB) demonstrated an 83.7% 
resolution of diabetes compared with restrictive procedures such as the 
laparoscopically adjustable gastric band (LAGB) which achieves a 47.9% 
resolution (Moo & Rubino, 2008). The concept of complete and long-term 
diabetes remission is demonstrated in the normalization of blood glucose levels, 
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insulin, HbA1c and the discontinuation of diabetes medications. If the anti-
diabetic effect of gastrointestinal bypass procedures is not unique to the obese 
population and the mechanism appears to be independent of weight loss and 
caloric intake, it becomes evident that gastrointestinal bypass surgery can no 
longer be seen solely as a therapy for obesity (Moo & Rubino, 2008). This 
supports the new concept of diabetes surgery, one in which a surgical 
intervention is intentionally used to treat diabetes.  
  
Purpose of the Study 
As the incidence of type II diabetes continues to rise worldwide at 
epidemic proportions, endeavors to find more effective therapies increase. 
Gastrointestinal bypass surgery is now gaining awareness as a potentially 
effective and long-term treatment. The purpose of this paper is to conduct a 
systematic review of gastrointestinal bypass surgery on the glycemic control and 
insulin resistance of type II diabetes and to analyze the outcomes using the 
Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) system.  
METHOD 
 
An extensive literature search was performed using Medline. This 
database was accessed through the Pacific University Library system. The 
keywords searched were “bariatric surgery” and “diabetes mellitus, type 2” 
individually and in combination. The search was limited to human subjects, full 
text, English language and evidence based medicine reviews. Articles older than 
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three years were excluded. The initial results included 8 articles. Of the 8 articles, 
only one article was a randomized controlled trial directly comparing gastric 
banding and conventional therapy and was selected for review.  
Another extensive literature search was performed using Pubmed. The 
keywords searched were “glucose metabolism” “type 2 diabetes” and “bariatric 
surgery” individually and in combination. The search was limited to human 
subjects, full text and English language. Articles older than five years were 
excluded as well as articles that did not appear to be relevant to the topic. The 
initial results included 3 articles. Two articles were excluded because they were 
reviews and the remaining article was included.  
Another literature search was performed using Uptodate. The keywords 
searched were “roux en y” individually. An article titled “Surgical management of 
severe obesity” was perused and found to have a section on treatment for type II 
diabetes. The articles that were cited in this section were sought out using 
Medline using their respective title and author. This resulted in one randomized 
control trial. A total of three articles were selected for review.  
RESULTS 
From the years 2005-2010, there were a total of three published articles 
that discussed gastric bypass surgery and the positive effects it had on 
controlling type II diabetes mellitus in terms of improving glycemic control and 
increasing insulin sensitivity. The three studies all used fasting plasma glucose 
and HbA1c as pre and post-operative markers of diabetic improvement. Two of 
the studies also used the Homeostasis Model Assessment – insulin resistance 
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(HOMA-ir) index, both pre and postoperatively, as well as plasma insulin levels. 
The HOMA index is derived from fasting plasma glucose and insulin levels and is 
an excellent way to assess insulin resistance.  
Dixon, O’Brien, Playfair and Chapman (2008), studied the effects of 
adjustable gastric banding (AGB) and conventional therapy (CT) on type II 
diabetes. Recruitment commenced in December 2002, and all data was available 
for analysis in December 2006. This study was a randomized control trial that 
allocated sixty patients into two treatment groups. Thirty patients received CT 
(diet/exercise), and thirty patients received laparoscopic AGB. One patient 
randomized to surgery withdrew from the study on the evening prior to the 
scheduled operation and didn’t agree to further follow up. The remaining twenty-
nine surgically treated patients completed the two-year program. Of the 
conventionally treated patients, twenty-six completed the two-year assessment. 
Pre-operatively in the surgical group, the mean HbA1c levels were 7.8%, plasma 
glucose levels were 156.7 and plasma insulin levels were 19.7, and in the CT 
group it was 7.6%, 158.0 and 18.7, respectively (Table 1, Appendix B). 
Remission of type 2 diabetes was achieved by twenty six participants at two 
years (73%) randomized to the surgical program and four (13%) to the 
conventional therapy program (p<.001). This represented 76% and 15% 
remission rates among those who completed the follow-up in the surgery and 
conventional therapy groups. Mean levels of HbA1c, fasting plasma glucose and 
insulin levels were significantly lower in the surgical group at two years. HbA1c 
levels were 6.0% with a decrease of 1.81, plasma glucose levels were 105.6 with 
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a decrease of 51.2, and plasma insulin levels were 9.8 with a decrease of 12.4 
(Table 2, Appendix C). The CT group had HbA1c levels at 7.21% with a 
decrease of 0.38, plasma glucose levels were 139.6 with a decrease of 18.4 and 
plasma insulin levels were 24.1 with an increase of 1.0 (Table 2, Appendix C). 
Insulin resistance was calculated preoperatively and again at the two-year follow 
up. The HOMA-ir score was 1.90 in the surgical group with a decrease of 45.5, 
and in the CT group it was 3.50 with a decrease of 3.3 (Table 2, Appendix C). Of 
these results, the HbA1c, plasma glucose, plasma insulin and HOMA-ir were 
statistically significant with a p-value<0.05. The HbA1c had a p-value<.001 with a 
95% CI (-2.1 to -0.80). The plasma glucose had a p-value=.002 with a 95% CI (-
53.1 to -12.3). The plasma insulin had a p-value<.001 with a 95% CI( -19.6 to -
7.3), and the HOMA-ir had a p-value<.001 with a 95% CI (-57 to -26.8). There 
was also a significant reduction in the use of pharmacotherapy for glycemic 
control in the surgical group at two years. At baseline, two surgically treated and 
four conventionally treated were not using pharmacotherapy; at two years, the 
numbers were twenty-six and eight, respectively. In the surgical group at two 
years there were fewer using metformin (3 vs. 28, P<.001) and other 
hypoglycemic therapy (1 vs. 9, p=0.006). The one surgical patient using insulin at 
baseline was in remission at two years. There were no significant changes in the 
use of therapy in the group randomized to receive conventional therapy.  
Torquati, Lutfi, Abumrad and Richards (2005), studied whether or not the 
roux-en-y gastric bypass (RYGB) was the most effective treatment for type II 
diabetes mellitus in morbidly obese patients. This study was a prospective cohort 
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that was conducted at Vanderbilt University Medical Center that enrolled 117 
consecutive patients over a thirty-month period who were morbidly obese with 
type II diabetes who were undergoing laparoscopic RYGB. The primary outcome 
measured was the resolution of type II diabetes and the secondary endpoints 
measured fasting plasma glucose and HbA1c at one-year follow-up. Ninety-
seven patients (83%) completed the one-year follow-up clinic visit. The fasting 
plasma glucose and HbA1c levels significantly decreased after RYGB. At the six 
and twelve months postoperative mark, the levels were still low but had seemed 
to plateau. At baseline, fasting plasma glucose levels were 164, at six months 
they were 104 and at twelve months they were 101 (Table 3, Appendix D). The 
two-sided p-value was statistically significant at p<.0001. For HbA1c, at baseline 
it was 7.7%, at six months it was 6.1% and at twelve months it was 6.0%, the 
two-sided p-value was statistically significant at p<.0001 (Table 3, Appendix D). 
Complete resolution of type II diabetes was achieved in seventy-two patients 
(74%). All of the remaining twenty-five patients decreased the daily medication 
requirements (partial resolution). The cohort of patients was then divided into two 
groups: complete type II diabetes resolution, n=72 and partial type II diabetes 
resolution, n=25. Preoperative waist circumference was a significant predictor for 
resolution of type II diabetes. The complete response group had a significantly 
smaller waist circumference than the partial response group. Type of medical 
treatment was also a significant predictor of successful outcome, with patients 
treated only with oral hypoglycemic medications achieving a higher percentage of 
complete response than patients treated with insulin. Complete resolution of type 
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II diabetes was also associated with a lower preoperative level of HbA1c. The 
preoperative HbA1c in the complete resolution group was 7.5% +/- 1.3, whereas, 
the partial resolution group had a HbA1c of 8.6 +/- 1.7, and the two-sided p-value 
was .001.  
Peterli, Wolnerhanssen, Peters and Devaux (2009), studied the 
improvement in glucose metabolism following the laparoscopic roux-en-y gastric 
bypass (RYGB) or the laparoscopic sleeve gastrectomy (LSG) surgery. This 
study was a randomized, prospective, parallel group trial that used a computer-
generated program to randomize twenty-seven patients to either LRYGB or LSG. 
After randomization, thirteen patients underwent LRYGB and fourteen LSG. 
None of the patients in the LRYGB had type II diabetes, whereas three patients 
in the LSG group did. With the exception of one patient in the LSG group, all 
other patients in both groups had an abnormal HOMA-ir index >3.8, indicating 
insulin resistance. In the LRYGB group, baseline levels for glucose (mmol/L), 
insulin (U/mL) and the HOMA-ir were 5.7, 28.3 and 9.1 (Table 4, Appendix E). In 
the LSG group, baseline levels for glucose, insulin and the HOMA-ir were 6.3, 
37.0 and 9.1 (Table 5, Appendix F). At one week postoperatively the patients 
who underwent LRYGB, the glucose, insulin and HOMA-ir levels were 5.6, 21.6 
and 6.1 and at three months postoperatively, these same levels were 5.1, 14.9 
and 3.4 (Table 4, Appendix E). At one week post-op the patients who underwent 
LSG, the glucose, insulin and HOMA-ir levels were 5.5, 23.9 and 6.0 and at the 
three months postoperatively, these same levels were 5.4, 24.2 and 4.0 (Table 5, 
Appendix F). The p-value between the two groups using the HOMA-ir was 
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statistically significant at the one week mark, p = 0.018, and three month mark, 
p<.0001. Postoperatively, fasting insulin concentrations were reduced in both 
groups. An improvement in the HOMA-ir was seen as early as one week 
postoperatively in both groups, and most subjects were found to be as insulin 
sensitive as lean normal weight subjects three months after the operation. Two of 
the three patients with manifest diabetes were euglycemic without medication, 
and one with long standing type 2 diabetes showed significant improvement but 
was still insulin dependent.  
DISCUSSION 
The primary goal of this review was to examine the effectiveness of gastric 
bypass surgery with regards to improvement of glycemic control in type II 
diabetes. The use of gastric bypass surgery as a treatment option remains a 
difficult area to research due to the lack of completed studies directly comparing 
the results of gastric bypass with no surgical intervention. A single study in this 
trial only used twenty-seven patients as part of the subject group, however, it was 
designed as a randomized control trial and the outcome was sufficient to be 
relevant to the review. The other studies clearly reported the flow of the 
participants through the trials and reported a large enough sample size.  The 
trials all had a sufficient follow-up period ranging from three months to two years.  
According to Dixon et al. (2008), the group that underwent surgery 
displayed a five times higher remission rate and four times greater reduction in 
HbA1c values than the conventionally treated group. In addition to superior 
glycemic control, this study also confirmed that there were significant 
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improvements in insulin sensitivity as well as a reduction in the use of oral 
diabetic medications in the surgical group. This randomized trial demonstrated 
that weight loss associated with gastric banding resulted in diabetes remission in 
the majority of obese participants recently diagnosed (<2 years), and was 
associated with greater improvement in the use of related medications. This 
study has provided a high level of evidence in the form of a randomized 
controlled trial in supporting the consideration of bariatric surgery as a treatment 
option for type II diabetes.  
In the study conducted by Torquati et al. (2005), the results clearly 
demonstrated that RYGB achieves better glycemic control than the most 
effective medical treatments. RYGB had a significantly greater decrease in 
HbA1c and a decreased requirement for diabetes medications than a low-calorie 
diet. Twelve months after RYGB surgery, a mean HbA1c decrease of 1.7%, and 
74% of patients were not taking any anti-diabetic medications in comparison to 
the patients treated with a low calorie diet who only experienced a 0.6% 
reduction in HbA1c and only 26% of patients were taking reduced doses of 
diabetes medications; none were able to discontinue anti-diabetic medications. 
This study clearly showed that the RYGB is highly effective in achieving excellent 
glycemic control in patients with type II diabetes, although the low-grade score 
renders further research necessary. 
According to Peterli et al. (2009), both the LRYGB and LSG procedures 
were associated with an amelioration in glycemic control which was seen as 
early as eight to ten days after either of the two procedures, as measured by both 
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the glucose and insulin plasma levels. The HOMA-ir index was significantly 
improved in most subjects, with the majority of patients found to be as insulin 
sensitive as lean, normal-weight subjects three months after the operation. 
Although this study was conducted as a randomized control trial, only three 
diabetic patients were included in the LSG surgical group. However, this does not 
appear to have skewed the data, as the LRYGB was expected to show better 
glycemic control in comparison to the LSG. Surprisingly, the LSG patients 
showed a similar improvement in glucose metabolism despite having all three 
diabetic patients, two of whom had a complete resolution of their diabetes within 
three months of the operation. This further strengthens the picture that gastric 
bypass surgery as a whole rapidly improves glycemic control in type II diabetic 
patients, although GRADE gives this test a moderate score distinguishing it from 
Dixon et al. (2008).  
The outcomes reviewed for this systematic review were fasting plasma 
glucose (FPG), HbA1C, insulin levels and diabetes remission. All were of 
moderate quality after being reviewed by the GRADE system, giving the 
evidence a grade of moderate overall (Appendix A). A moderate grade means 
that further research is likely to have an important impact on our confidence in 
the estimate of effect and may change the estimate overall. The randomized 
control trial conducted by Peterli et al. was deducted one point for only having 
twenty-seven participants in the study. With such a small sample size, the results 
could be considered imprecise, thus having a wide confidence interval around 
the estimate of effect for FPG and HbA1C.  The remaining outcomes of diabetes 
 16
remission and insulin levels were neither up or downgraded in both of the 
randomized control trials as well as the cohort study. Both of the randomized 
control trials were given a starting grade of high, and the cohort due to being an 
observational study, was given a starting grade of low.  
CONCLUSION 
There is now considerable evidence that operations previously performed 
as weight loss procedures may have the added benefit of improving glycemic 
control and inducing long term diabetes remission. As demonstrated in this 
systematic review, gastric bypass surgeries be they RYGB, LSG or LAGB, 
should be performed for whom pharmacotherapy has proven ineffective. The 
concept of complete and long-term diabetes remission was demonstrated in the 
normalization of blood glucose levels, insulin, HbA1c and the discontinuation of 
diabetes medications in a large number of patients. This systematic review 
supports the new concept of ‘diabetes surgery’, one in which a surgical 
intervention is intentionally used to treat diabetes. Further research is likely to 
support this conclusion.  
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Table 1. Baseline Characteristics of Participants 
Characteristic Surgery (n=30) Conventional Therapy (n=30) 
HbA1c mean (SD), % 7.8 (1.2) 7.6 (1.4) 
   
Plasma glucose mean (SD), 
mg/dL 
156.7 (38.5) 158.0 (48.7) 
   
Plasma insulin median (IQR), 
uIU/mL) 
19.7 (16.5-27.5) 18.7 (13.7-30.7) 
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Table 2. Primary and Secondary Outcomes at 2 years 
Variable Surgery (n=30) Conventional Therapy (n=30) 
Remission of Diabetes No. (%) 22 (73) 4 (13) 
   
HbA1c % 6.0 (0.82) 7.21 (1.39) 
Plasma glucose, mg/dL 105.6 (30.3) 139.6 (38.1) 
Plasma insulin, µIU/mL 9.8 (4.7) 24.1 (13.6) 
HOMA-IR 1.90 (0.73) 3.50 (0.97) 
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Table 3. Effect of Gastric Bypass on the glucose metabolism 
 Fasting plasma glucose (mg/dL) HbA1C (%) 
 22
Baseline 164 +/- 55 7.7 +/- 1.5 
   
6 months 104 +/- 43 6.1 +/- 1.3 
   
12 months 101 +/- 38 6.0 +/- 1.1 
   
Two-sided p-value .0001 .0001 
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Table 4. HOMA Index, Glucose and Fasting Insulin Before, and 1 week and 3 
months postoperatively after LRYGB: Mean +/- SD and (Range) 
Parameter                 Preoperative 1 week 3 months 
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HOMA Index            9.1 +/- 1.2 6.1 +/- 0.7 3.4 +/- 0.3 
   
Glucose                     5.7 +/- 0.8 
(mmol/L)                    
5.6 +/- 0.7 5.1 +/- 0.5 
   
Insulin                     28.3 +/- 13.3 21.6 +/- 5.2 14.9 +/- 3.7 
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Table 5. HOMA index, Glucose and Fasting Insulin Before, and 1 weeks and 3 
months postoperatively after LSG: Mean +/- SD and (Range) 
Parameter                 Preoperative 1 week 3 months 
HOMA Index            9.1 +/- 1.7 6.0 +/- 1.4 4.0 +/- 0.6 
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Glucose                     6.3 +/- 1.8 5.5 +/- 1.9 5.4 +/- 1.0 
(mmol/L)   
   
Insulin                     37.0 +/- 26.1 23.9 +/- 15.7 24.2 +/- 17.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
